New Delhi, January 17: The Drugs Controller General of India (DCGI) has approved the market authorisation of Serum Institute of India's (SII) COVID-19 vaccine Covovax as a heterologous booster dose. This vaccine can be taken as a booster dose by people who have already taken two doses of Covishield or Covaxin.

Earlier, the DCGI approved Covovax for restricted use in emergency situations in adults on December 28, 2021. It was approved for teenagers aged between 12-17 on March 9, 2022, and for children aged 7 to 11 on June 28, 2022, subject to certain conditions. DCGI Approves Market Authorisation for SII’s COVID-19 Vaccine ‘Covovax’ As Heterologous Booster Dose.

Covovax is manufactured through technology transfer from Novavax. It has been approved by the European Medicines Agency for conditional marketing authorization. It was granted an emergency-use listing by the World Health Organization (WHO) on December 17, 2021.

Recently, Bharat Biotech's nasal Covid vaccine for adults above 18 years was approved by the Government of India and will also be used as a heterologous booster dose. COVID-19 Vaccine Side Effects: Vaccines or Villains? Government Admits Multiple Side-Effects of Coronavirus Jabs in RTI Reply.

The vaccine will be available in private hospitals and will be included in the Covid-19 list of vaccines. iNCOVACC is the world's first Intranasal Vaccine to receive both Primary series and Heterologous booster approval.

(The above story is verified and authored by ANI staff, ANI is South Asia's leading multimedia news agency with over 100 bureaus in India, South Asia and across the globe. ANI brings the latest news on Politics and Current Affairs in India & around the World, Sports, Health, Fitness, Entertainment, & News. The views appearing in the above post do not reflect the opinions of LatestLY)